Pregnant women with hepatitis b: which drug is safer?

NCT ID NCT07668934

ENROLLING_BY_INVITATION Disease control Sponsor: The Third Affiliated Hospital of Guangzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at two antiviral drugs, TAF and TDF, in pregnant women with chronic hepatitis B. It aims to see which one better controls the virus and keeps the mother's liver healthy without harming the baby. About 816 women in early or middle pregnancy will take one of the drugs until delivery and be followed for outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF)
What this could lead to: If successful, this could show that TAF is a safer option for pregnant women with hepatitis B, reducing liver issues and protecting the baby from infection.
What could go wrong: This is a phase 4 study, but results may not apply to all women. Risks include potential side effects for mother or baby, and the study does not aim to cure hepatitis B.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY PREGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EARLY PREGNANCY HEPATITIS B INFECTION PREGNANT WOMEN

Contacts and locations

Locations

The Third Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.